Dipeptidyl peptidase-4 activity is associated with urine albumin excretion in type 1 diabetes

Journal of Diabetes and its Complications

Volumn 31, Issue 1, 2017, Pages 218-222

  Duvnjak, Lea ^a,b   Perković, Matea Nikolac ^c   Blaslov, Kristina ^a  

^a University of Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Albuminuria; Diabetic kidney disease; Dipeptidyl peptidase 4; Glycaemic control; Hypertension; Type 1 diabetes mellitus

Indexed keywords

ALBUMIN; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV; HEMOGLOBIN A1C; BIOLOGICAL MARKER; DPP4 PROTEIN, HUMAN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGE; AGED; ALBUMINURIA; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME ACTIVITY; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; WAIST CIRCUMFERENCE; BLOOD; COMPLICATION; CROATIA; DIABETIC NEPHROPATHY; DISEASE EXACERBATION; ENZYMOLOGY; KIDNEY; KIDNEY FAILURE; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; UNIVERSITY HOSPITAL; UPREGULATION; URINE; YOUNG ADULT;

ADULT; AGED; ALBUMINURIA; BIOMARKERS; CROATIA; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DIPEPTIDYL PEPTIDASE 4; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; GLYCATED HEMOGLOBIN A; HOSPITALS, UNIVERSITY; HUMANS; KIDNEY; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; UP-REGULATION; YOUNG ADULT;

EID: 84992688688     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2016.08.022     Document Type: Article

References (33)

1. Adler, AI, Stevens, RJ, Manley, SE, Bilous, RW, Cull, CA, Holman, RR, UKPDS GROUP, Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes study (UKPDS 64). Kidney International 63 (2003), 225–232.
2. Alter, ML, Ott, IM, von Websky, K, et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney & Blood Pressure Research 36:1 (2012), 119–130.
3. Blaslov, K, Bulum, T, Duvnjak, L, Circulating dipeptidyl peptidase-4 activity is associated with insulin resistance in type 1 diabetic patients. Journal of Diabetes and its Complications 29:3 (2015), 390–394.
4. Blaslov, K, Bulum, T, Duvnjak, L, Circulating dipeptidyl peptidase-4 activity is associated with diabetic retinopathy in type 1 diabetic patients. European Journal of Ophthalmology 25:4 (2015), 328–332.
5. Caramori, ML, Kim, Y, Huang, C, et al. Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes. Diabetes 51 (2002), 506–513.
6. Cernea, S, Raz, I, Therapy in the early stage: incretins. Diabetes Care 34:Suppl. 2 (2011), S264–S271.
7. Cooper, ME, Perkovic, V, McGill, JB, et al. Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. American Journal of Kidney Diseases 66:3 (2015), 441–449.
8. Dronavalli, S, Duka, I, Bakris, GL, The pathogenesis of diabetic nephropathy. Nature Clinical Practice. Endocrinology & Metabolism 4 (2008), 444–452.
9. Firneisz, G, Varga, T, Lengyel, G, et al. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PloS One, 5(8), 2010, e12226.
10. Foley, R, Murray, AM, Li, S, Herzog, CA, McBean, AM, Eggers, PW, Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999. Journal of the American Society of Nephrology: JASN 16 (2005), 489–495.
11. Hocher, B, Reichetzeder, C, Alter, ML, Renal and cardiac effects of DPP4 inhibitors– from preclinical development to clinical research. Kidney & Blood Pressure Research 36:1 (2012), 65–84.
12. Iwabuchi, A, Kamoda, T, Saito, M, Nozue, H, Izumi, I, Hirano, T, Sumazaki, R, Serum dipeptidyl peptidase 4 activity in children with type 1 diabetes mellitus. Journal of Pediatric Endocrinology & Metabolism 26:11–12 (2013), 1093–1097.
13. Jefferson, JA, Shankland, SJ, Pichler RH proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney International 74:1 (2008), 22–36.
14. Kanasaki, K, Shi, S, Kanasaki, M, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 63:6 (2014), 2120–2131.
15. Kodera, R, Shikata, K, Kataoka, UO, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54:4 (2011), 965–978.
16. Kramer, CK, Leitão, CB, Pinto, LC, Silveiro, SP, Gross, JL, Canani, LH, Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care 30 (2007), 1998–2000.
17. Lazzara, MJ, Deen, WM, Model of albumin reabsorption in the proximal tubule. American Journal of Physics 292:1 (2007), F430–F439.
18. Lemley, KV, Blouch, K, Abdullah, I, et al. Glomerular permselectivity at the onset of nephropathy in type 2 diabetes mellitus. Journal of the American Society of Nephrology 11:11 (2000), 2095–2105.
19. Levey, AS, Stevens, LA, Schmid, CH, Zhang, YL, Castro, AF III, Feldman, HI, et al. A new equation to estimate glomerular filtration rate. Annals of Internal Medicine 150 (2009), 604–612.
20. Liu, L, Liu, J, Wong, WT, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 60 (2012), 833–841.
21. Mentlein, R, Dipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptides. Regulatory Peptides 85 (1999), 9–24.
22. Mogensen, CE, Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 42 (1999), 263–285.
23. Mogensen, CE, Poulsen, PL, Epidemiology of microalbuminuria in diabetes and in the background population. Current Opinion in Nephrology and Hypertension 3 (1994), 248–256.
24. Pagtalunan, ME, Miller, PL, Jumping-Eagle, S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. The Journal of Clinical Investigation 99:2 (1997), 342–348.
25. Reutens, AT, Epidemiology of diabetic kidney disease. The Medical Clinics of North America 97 (2013), 1–18.
26. Ruan, XZ, Moorhead, JF, Fernando, R, Wheeler, DC, Powis, SH, Varghese, Z, Regulation of lipoprotein trafficking in the kidney: role of inflammatory mediators and transcription factors. Biochemical Society Transactions 32 (2004), 88–91.
27. Ruster, C, Wolf, G, Renin-angiotensin-aldosterone system and progression of renal disease. Journal of the American Society of Nephrology: JASN 17 (2006), 2985–2991.
28. Steinberg, D, Thematic review series: the pathogenesis of atherosclerosis – an interpretive history of the cholesterol controversy, part III: mechanistically defining the role of hyperlipidemia. Journal of Lipid Research 46 (2005), 2037–2051.
29. Sun, AL, Deng, JT, Guan, GJ, et al. Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease. Daibetes & Vascular Disease Research 9:4 (2012), 301–308.
30. Tanaka, Y, Kume, S, Chin-Kanasaki, M, et al. Renoprotective effect of DPP-4 inhibitors against free fatty acid-bound albumin-induced renal proximal tubular cell injury. Biochemical and Biophysical Research Communications 470:3 (2016), 539–545.
31. Tsuprykov, O, Ando, R, Reichetzeder, C, et al. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy. Kidney International 89:5 (2016), 1049–1061.
32. Vučić Lovrenčić, M, Radišić Biljak, V, Božičević, S, Prašek, M, Pavković, P, Knotek, M, Estimating glomerular filtration rate (GFR) in diabetes: the performance of MDRD and CKD-EPI equations in patients with various degrees of albuminuria. Clinical Biochemistry 45:18 (2012), 1694–1696.
33. Xu, R, Sun, S, Huo, Y, Yun, L, Huang, S, Li, G, Yan, S, Effects of ACEIs versus ARBs on proteinuria or albuminuria in primary hypertension: a meta-analysis of randomized trials. Medicine (Baltimore), 94(39), 2015, e1560.